Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 8/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10222934 | 0.87 | HRH3 (0.53) | SMYD3PARP1HRH3 | |
| SCHEMBL532300 | 0.82 | PARP1 (0.47) | SMYD3PARP1HTR1AHTR7KCNH2 | |
| SCHEMBL4185512 | 0.80 | HTR1A (0.55) | PARP1HTR1A | |
| SCHEMBL23842802 | 0.80 | PARP1 (0.50) | SMYD3PARP1HTR1AHTR7KCNH2 | |
| SCHEMBL532182 | 0.80 | PARP1 (0.65) | SMYD3PARP1 | |
| SCHEMBL533459 | 0.78 | PARP1 (0.51) | SMYD3PARP1HTR1AHTR7KCNH2 | |
| SCHEMBL531980 | 0.78 | SMYD3 (0.59) | SMYD3PARP1HRH3 | |
| SCHEMBL23830906 | 0.78 | HRH3 (0.42) | SMYD3PARP1HTR1AHTR7KCNH2 | |
| SCHEMBL532159 | 0.77 | PARP1 (0.68) | SMYD3PARP1 | |
| SCHEMBL4196161 | 0.74 | HTR1A (0.51) | PARP1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | SMYD3 3712/4885PARP1 1/4885HTR1A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.